PBM

Psyence Biomedical Ltd. (NASDAQ:PBM) is a Canadian biotechnology company founded in 2020 and publicly traded since December 2021. The company specializes in developing botanical psilocybin-based psychedelic medicines for treating mental health conditions, particularly in palliative care settings. Based in Toronto, Canada, Psyence operates as a subsidiary of Psyence Group Inc. and represents one of the emerging players in the nascent psychedelic medicine industry, focusing on naturally-sourced psilocybin rather than synthetic alternatives.